Last reviewed · How we verify

DUSA Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

DUSA Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Biofrontera Bioscience GmbH · 1 shared drug class
  2. Galderma R&D · 1 shared drug class
  3. Joint Authority for Päijät-Häme Social and Health Care · 1 shared drug class
  4. National Cancer Center, Korea · 1 shared drug class
  5. Photocure · 1 shared drug class
  6. Psoriasis Treatment Center of Central New Jersey · 1 shared drug class
  7. Steba Biotech S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for DUSA Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). DUSA Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dusa-pharmaceuticals-inc. Accessed 2026-05-16.

Related